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Abstract This article gives a comprehensive overview of
cytokine and other inflammation associated protein levels in
plasma, serum and cerebrospinal fluid (CSF) of patients with
Alzheimer’s disease (AD) and mild cognitive impairment
(MCI). We reviewed 118 research articles published between
1989 and 2013 to compare the reported levels of 66 cytokines
and other proteins related to regulation and signaling in in-
flammation in the blood or CSF obtained from MCI and AD
patients. Several cytokines are evidently regulated in (neuro-)
inflammatory processes associated with neurodegenerative
disorders. Others do not display changes in the blood or
CSF during disease progression. However, many reports on
cytokine levels in MCI or AD are controversial or inconclu-
sive, particularly those which provide data on frequently
investigated cytokines like tumor necrosis factor alpha
(TNF-α) or interleukin-6 (IL-6). The levels of several cytokines
are possible indicators of neuroinflammation in AD. Some of
them might increase steadily during disease progression or
temporarily at the time of MCI to AD conversion. Furthermore,
elevated body fluid cytokine levels may correlate with an
increased risk of conversion from MCI to AD. Yet, research
results are conflicting. To overcome interindividual variances
and to obtain a more definite description of cytokine regulation
and function in neurodegeneration, a high degree of methodical
standardization and patients collective characterization, together
with longitudinal sampling over years is essential.
Keywords Neuroinflammation . Cytokines . Serum .
Cerebrospinal fluid .Mild cognitive impairment .Alzheimer’s
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Introduction
Cytokines are small signaling proteins with a large spectrum
of functions in inflammatory processes and immune system
regulation [1]. Therefore, they have been investigated in the
context of neuroinflammation, a process accompanying and
probably contributing to pathology in several neurodegenera-
tive diseases including Alzheimer’s disease (AD) or
Parkinson’s disease (PD) [2–5]. One key feature of neuroin-
flammation is activation of microglia, which includes local
changes of cytokine expression [2, 3]. Additionally, systemic
levels of cytokines may rise in response to aging and stress,
known risk factors for neurodegeneration [6–8]. Susceptibility
for inflammation rises with age and might be enhanced by
each inflammatory event [9]. Furthermore, chronic inflamma-
tion and the delirium accompanying severe systemic infection
have been shown to be risk factors for AD in the elderly, and
vice versa, several risk factors for AD are also inducers of
systemic inflammation [10–13]. As a consequence, levels of
cytokines, their receptors and other proteins associated with
immune responses in blood and CSF of AD patients have
been frequently investigated to uncover mechanisms of neu-
roinflammation in dementia or in the context of biomarker
research. However, much of the data obtained from different
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studies is controversial. Here, we give a comprehensive over-
view of published research in this field and discuss possible
reasons behind the conflicting observations.
Results
Literature Overview
We included 118 PubMed-listed articles providing data ex-
plicitly on levels of immune signaling proteins—primarily
cytokines and their receptors—in serum, plasma or CSF of
patients with diagnosed MCI or AD in comparison to unaf-
fected control groups. We excluded studies on cytokine levels
in human or murine brain tissue, cytokine production by
lymphocytes, cytokine polymorphisms or cytokine levels in
other neurodegenerative diseases, like PD or frontotemporal
dementia. In total, the 118 articles reported data on 66 cyto-
kines, cytokine receptors and other proteins induced by cyto-
kines or otherwise associated with inflammatory signaling and
regulation.
Table 1 gives a short summary of literature features: In
general, about one third of the articles investigated MCI or
other dementia types additional to AD. Plasma, serum and
CSF were used in equal terms, and the most frequent method
for cytokine determination was singleplex enzyme-linked im-
munosorbent assay (ELISA). By the last decade, multiplex
assays and cytokine arrays were used with increasing frequen-
cy. A variety of cognition testing methods and diagnostic
criteria were used in the different studies, althoughmost articles
noted the use of the National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA) criteria and mini-mental state examination (MMSE)
for patient characterization [14, 15]. Supplementary 1 contains
a more detailed description of the reviewed articles contents,
investigated proteins and used methods.
General Observations
A brief overview of the described regulations of different
cytokines and inflammation associated proteins is given in
Table 2. A list of observed effects and used methods for each
protein is given in Supplementary 2. Above all, there is a
tendency that with growing number of research papers on a
particular cytokine there is also an increase in contradictions.
For instance, the most frequently investigated cytokines, tu-
mor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6),
described in 20–25 % of articles, are reported as upregulated,
not regulated or downregulated in the blood or CSF of AD
patients (see below, Table 2 and Supplementary 2).
One explanation for the conflicting results could be differ-
ences between the technical approaches of the studies.
However, methodological differences alone may not be the
solemn source of the variances, as many of the studies used
comparable methods: Over 75% of reviewed articles obtained
results from singleplex ELISA using recombinant protein
standards for absolute quantification of cytokines (Table 1).
It is possible that different ELISA kits do not give identical
absolute values of the same analyte [16]. Yet, this cannot
explain why different studies reported cytokine levels in AD
patients to be higher, unchanged or lower when comparing to
control groups. Further, studies using cytokine array technol-
ogy in a methodological comparable manner also did not
provide reproducible results, which indicates that not only
technical differences cause conflicting results in cytokine
analysis [17–19]. The same applies for other multiplex plat-
forms (e.g., Luminex® platform): Despite high methodical
similarities, there were considerable differences in sensitivity,
specificity and composition of biofluids-based multianalyte
patterns for differentiation between MCI and AD patients and
controls [20–25].
Table 1 Characteristics of reviewed articles on cytokine levels in AD and
MCI. The table lists investigated disease type, diagnostic criteria/tests,
sample types and methods of the reviewed 118 articles (Supplementary
1). Note that some articles investigated more than one disease or body
fluid or used more than a single method. Roughly 1/3 of articles inves-
tigated MCI or other dementia types additionally to AD. Most studies
reported use of at least one class of diagnostic criteria and one type of
cognitive testing. Plasma, serum and CSF were used in equal terms, and
the most frequent method was singleplex ELISA, followed especially in
the last decade by multiplex assays and cytokine arrays. The percentages
reflect the respective proportion assessing the respective features
Disease type 96 % Alzheimer’s disease
38 % Mild cognitive impairment









Sample type 38 % Plasma
40 % Serum
37 % CSF
Methods 77 % ELISA (singleplex)
8 % Multiplex assay
4 % Cytokine array
3 % Western blot
4 % Cell-based bioassays
6 % Immunodiffusion (solemnly for quantification
of ACT)
4 % Other methods (radioimmunoassay,
immunoephelometry, qRT-PCR)
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Taken together, these observations point to other critical
factors, like patient collective composition and patient char-
acterization. For example, it has been shown that cytokine
profiles correlate to amyloid burden or APOE genotype,
which might be of particular importance for the investigation
of such proteins in AD [21, 26]. In this context, it is interesting
that in some articles AD patient collectives were subdivided
by severity of disease. These reports found differences in
cytokine levels between mild, modest or severe AD, e.g.,
studies by Motta et al., Baranowska-Bik et al., Galimberti
et al. [27–29]. Other studies outlined correlations between
cytokine levels and disease risk, progression or MCI to AD
conversion [27, 29–48]. Yet, a recent meta-analysis of
Koyama et al. came to the conclusion that elevation of periph-
eral cytokine levels is a modest risk factor for neurodegener-
ation in general, but unspecific for AD [49].
In many studies, strongest upregulation of cytokines was
observed in patients with mild AD indicating that cytokine
signaling might primarily play a role in the intermediate stages
of the disease. On the contrary, patients with advanced AD
showed less strong upregulation of cytokines or no differences
compared to controls. This might explain why in AD patient
collectives, which did not discriminate for disease progression
state, no differences to controls or simply higher variances in
the AD cohort were observed. Unfortunately, only few studies
provide data on disease duration, disease severity or results of
neuropsychological examinations likeMMSE, whichmakes it
difficult to compare these studies.
Another interesting observation is that some cytokines, espe-
cially those apparently not regulated in AD (e.g., interleukin-2,
IL-2) where less controversial between studies than cytokines
frequently reported to be regulated in any direction (like TNF-α,
see Supplementary 2). Thus, the latter still provide interesting
research targets, especially under the consideration that
subgrouping of patients might provide improved insights into
cytokine regulation in AD. In the following, we will give a more
detailed description of the regulation of selected cytokines:
TNF-α
TNF-α is one of the most frequently investigated cytokines.
From the 118 articles included, 13 articles describe




MCI AD MCI AD
↑ Upregulation BDNF, IL-1β, MIF,
MIP-4, RANTES
CTACK, FGF1, MIF, MIG,
sCD40, SCF, VEGF





ICAM-1, IFN-α, TNF-α ACT, ANG-2, IFN-α, IFN-γ,
IL-1β, IL-10, IL-11, IL-18a,
MIP-1α, sTNF-RI, VCAM-1
MCP-1a ACT, IL-1β, IL-1RII, IL-8,
IP-10, MCP-1a, VEGF
→ No regulation ACT, ANG-2, β-NGF, CD40L,
CTACK, EGF, G-CSF,
Eotaxin, GDNF, GRO-α, HGF,
IL-1α, IL-1RII, IL-2R, IL-3,
IL-6, IL-10, IL-11, IL-12, IL-
16, IL-18, IP-10, LIF, M-CSF,
MCP-1, MCP-3, MCP-4, MIG,
MIP-1δ, MIP-4α, PDGF-BB,




GRO-α, HGF, IGFBO-6, IL-
1RA, IL-1RII, IL-2, IL-2R, IL-





β-NGF, FGF2, GDNF, GM-
CSF, HGF, IFN-γ, IL-1RA,
IL-2, IL-2R, IL-10, IL-12a,
M-CSF, MIP-1α, SDF-1α,
sTNF-RI, sTNF-RII
→ No regulation +
↓ Downregulation
IL-8 G-CSF, IL-1α, IL-6R, MCP-3,
SDF-1α
BDNF, IL-6R





→ No regulation +
↓ Downregulation
BDNFa, CRP, EGF, GDNF,




Overview of the results of the reviewed articles, separated by observed protein expression regulations for serum/plasma and CSF as well asMCI andAD.
For several investigated proteins, multiple directions of regulation are described in different articles. For details on synonyms, frequency of effect
observation and used methods, see Supplementary 2
a Proteins for which disease progression-dependent regulation is described
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upregulation, 5 downregulation, and 15 no regulation of
TNF-α levels in plasma or serum of AD patients in compar-
ison to control groups [2, 17–19, 28, 32, 33, 35, 50–73]. In an
attempt to reduce these variances, we focused on ten articles
which report absolute values of plasma or serum TNF-α
concentration as obtained by ELISA, include patient group
sizes of n>10 and use the MMSE as an estimate of disease
severity [18, 28, 33, 35, 50, 52, 64, 68, 69, 74]. Among these
ten studies, six report no regulation and four modest upregu-
lation of TNF-α in blood, the latter mostly in patients with
severe AD. This might point to disease-state-dependent
changes of TNF-α blood levels. Furthermore, the mean values
for TNF-α in blood of controls range from 0.7 to 23.0 pg/ml
between the studies, pointing towards interassay variances.
Also, all studies show high interindividual variances and
overlaps between patient and control groups.
Studies analyzing TNF-α in the CSF of AD patients are
smaller in number but reflect the same picture: three studies
report upregulation of TNF-α, one downregulation and five
no regulation [2, 3, 58, 65, 75–79]. In MCI patients, two
studies report upregulation and three no regulation in plasma
or serum, whereas one study reports downregulation in CSF
[3, 19, 32, 51, 52, 63]. The variances between the studies are
therefore not limited to blood values.
As studies which reported increased TNF-α-levels often
investigated patients with severe AD, it is possible that the
levels of this cytokine increase slightly but continuously over
the time course of the disease. It is also possible that TNF-α is
only upregulated in subgroups of patients which have yet to be
defined, e.g., patients suffering from neuroinflammation in
addition to a neurodegenerative process.
TNF Receptors
A different picture is drawn for soluble variants of the TNF
receptors (sTNF-RI and sTNF-RII). The levels of both recep-
tors are mostly reported as unchanged in the blood or CSF of
AD patients in comparison to controls [32, 33, 50, 65, 75, 80,
81]. For MCI patients, however, data are controversial [32, 80,
82]. Follow up-studies show correlations of TNF receptor
levels with risk ofMCI to AD conversion [32, 83]. It is possible
that individuals with TNF receptor expression in the upper
tertile are at increased risk of developing AD. Yet, the observed
differences are too small to be used as reliable biomarkers.
Soluble CD40 and CD40 Ligand
Another member of the TNF receptor superfamily, soluble
CD40 (sCD40), is reported to be regulated in AD in a remark-
ably congruent manner: Three studies describe the elevation
of sCD40 plasma levels in AD patients [84–86]. A fourth
article by Buchhave et al. reports that levels of sCD40 posi-
tively correlate to risk of MCI to AD conversion [38]. Despite
variances in effect strength between the studies, sCD40 might
be an interesting target for biomarker research, especially
since it has not been investigated in CSF of AD or MCI
patients. Plasma levels of its binding partner CD40 ligand
(CD40L) are described as not regulated in MCI patients and
as upregulated in AD patients and might therefore represent
another biomarker candidate [38, 84].
IL-1β
IL-1β is another frequently investigated target in AD, whereas
only few reports describe levels in MCI. Interestingly, IL-1β
is mostly described as not regulated in CSF of AD patients,
while approximately 50 % of reports on serum or plasma
levels describe upregulation [2, 33, 35, 50, 53, 54, 56, 58,
65, 67, 71, 75, 76, 87–94]. The other 50 % of the studies on
IL-1β plasma levels in AD show slightly increased values in
patients, which are yet not statistically significant due to high
interindividual variances and overlaps between patients and
controls. Furthermore, no study reports downregulation of IL-
1β. Similar to TNF-α, it can be hypothesized that IL-1β is
only elevated in subgroups of patients or during certain dis-
ease stages. Also, peripheral IL-1β might increase slowly
during the time course of the disease. However, even if one
of these hypotheses is correct, the effects visible in the periph-
ery are probably small, as reflected by the large number of
studies showing no significant changes between AD patients
and controls. Therefore, it would be interesting to follow IL-
1β-levels in AD patients’ blood and CSF longitudinally.
IL-6
IL-6 has been examined in AD with similar frequency as
TNF-α, and with similar contradictory results [2, 28, 31, 34,
52–54, 58, 60, 61, 65, 67–69, 71, 75–77, 79, 87–89, 91, 92,
95–111]. We focused on articles reporting absolute concentra-
tions in collectives of at least 20 individuals. Both criteria
were fulfilled by 18 publications [28, 30, 31, 34, 52, 58, 68,
75, 79, 91, 94, 95, 102, 103, 107, 108, 112]. Most of the
studies show either upregulation or no regulation of IL-6 in
blood or CSF derived from AD patients. Noteworthy is that
only 2 of 18 studies report downregulation of IL-6 [75, 113].
These findings are similar between blood and CSF. Only one
study analyzed IL-6 levels in the blood of MCI patients but
reports no regulation [52].
When comparing the data, we made two observations
which might explain the conflicts: First, all included articles
showed large interindividual variances of IL-6 levels, some-
times ranging from 50–100 % of the reported mean values. As
a consequence, there is a high probability that comparisons in
small patient cohorts produce misleading data, as it is highly
probable that some individuals will show higher or lower
cytokine levels than others just by chance.
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Further, patients with severe AD showed higher plasma
levels of IL-6 than patients with less severe disease or healthy
controls. This could be interpreted in the way that peripheral
levels of IL-6 slightly increase over the time course of AD, as
shown by Kalman et al [31].
These observations much resemble those made for IL-1β
and TNF-α, and as before, intraindividual data over the time
course of disease would be the most promising way to obtain a
clearer picture regarding IL-6 levels.
IL-6 Receptors
Levels of soluble IL-6 receptor (sIL-6R) have been analyzed
in seven of the reviewed articles which investigated AD
patients, but not in MCI cases [75, 81, 101, 105, 109, 112,
114]. Each of these articles report either no regulation or
downregulation of sIL-6R in blood or CSF of AD patients.
Absolute values are relatively consistent between the studies,
ranging from approx. 20–220 ng/ml in serum and 0.5–
1.6 ng/ml in CSF. Similar to the cytokines described above,
high interindividual variances and a large overlap between
controls and patients were observed in all studies on sIL-6R.
Although the tendency to reduction of sIL-6R levels in AD is
apparently weak, none of the reviewed studies reported up-
regulation of this cytokine receptor. This is especially inter-
esting as IL-6 levels appear to increase slightly during AD. To
our knowledge, no study so far has analyzed the ratio of IL-6
to sIL-6R in AD or changes of this ratio over the time course
of disease. Again, it seems also possible that so far only
uncharacterized subgroups of AD patients display lower sIL-
6R levels compared to others.
IL-18
So far, all cytokines described in this review appear to increase
slowly with disease progression, while the respective recep-
tors might be decreased. Nevertheless, some cytokines present
a different picture. IL-18 has mostly been investigated in the
plasma and with at first glance contradictory findings: several
studies report no significant changes in IL-18 blood levels of
both MCI- and AD patients, although always with a tendency
to elevated levels [71, 115–117]. Two other studies show
elevation of blood levels in AD [118, 119]. Most of these
studies differed in the used ELISA kit and/or in patient cohort
characterization, which might be one reason for the observed
differences. Yet, there may be another possibility: In a study of
Motta et al., the patient cohort was divided according to
MMSE into mild, modest, and severe AD subgroups. These
authors showed that IL-18 levels were elevated in the early
stages of the disease, but later dropped again to levels equal to
those of controls [27]. After the initial rise, the following
decline of IL-18 levels occurred in a disease progression-
dependent manner. In other words, IL-18 levels reached a
peak in mild AD patients and correlated positively with the
MMSE afterwards. These findings would fit to several other
studies (e.g., [117, 119]) and support the concept of analyzing
AD subgroups. They also support the theory of neuroinflam-
mation as an early event in AD [120]. In this context, it is
interesting to note that no study analyzing IL-18 reports
effects in the plasma of MCI patients [71, 116, 117]. Together
with the results ofMotta et al., these findingsmay indicate that
IL-18 levels are elevated in the early phases of AD, possibly
during the turnover from “normal”MCI to AD. To our knowl-
edge, only one study analyzed IL-18 levels in CSF of AD
patients and found elevated levels of this cytokine [115]. It
should further be mentioned that IL-18-binding protein
(IL-18BP), a regulator of IL-18 function, has been de-
scribed as downregulated in AD, indicating that the
ratio of IL-18 and IL-18BP is influenced by regulation
of both proteins [119]. Summarized, IL-18—and possi-
bly its regulator IL-18BP—represent interesting candi-
dates to be analyzed in plasma and especially CSF of
well-characterized MCI and AD patients.
CCL2/MCP-1
MCP-1 has been analyzed in plasma and CSF of AD
and MCI patients. Although results were again contro-
versial, several studies find MCP-1 to be upregulated in
the CSF of AD and also MCI patients [121–123]. In
plasma, most articles report no regulation of MCP-1
[51, 70, 116, 121]. Only one study conducted by
Galimberti et al. investigated patients divided in MCI,
mild-modest AD and severe AD groups and revealed
elevated levels in MCI and mild-modest AD patients,
while subjects with severe AD showed lower levels
[29]. The effect strength was statistically significant,
yet modest in size and there were large overlaps be-
tween the groups. However, MCP-1 levels correlated to
MMSE after onset of MCI. This induction pattern is
highly similar to the one described by Motta et al. for
other cytokines and might be the result of innate im-
mune activation in the early stages of AD, as mirrored
by central and peripheral cytokine levels [27, 124].
CXCL10/IP-10
The 10-kDa interferon gamma-induced protein (IP-10) is re-
ported to be elevated in the CSF of MCI patients [82, 122].
After conversion fromMCI to AD, CSF levels drop again and
correlate over the time course of disease with MMSE scores
and cognitive decline [82, 122, 123]. In contrast, plasma levels
are uniformly reported to be unchanged in AD [70, 116, 121].
Therefore, IP-10 might resemble MCP-1 or IL-18 by showing
a peak of CSF levels only in early disease stages.
538 Mol Neurobiol (2014) 50:534–544
TGF-β
One of the cytokines showing the most inconsistent data is
TGF-β [27, 61, 78, 85, 94, 118, 125–131]. It has been pri-
marily investigated in AD and is described as not regulated,
upregulated, downregulated and regulated dependent on dis-
ease state. We focused on eight articles which used ELISA for
detection, but still found high variances in patient characteri-
zation and results [27, 78, 94, 127–131]. The mean values for
healthy controls ranged from 10 pg/ml to 60 ng/ml, most
likely derived from the lack of technical standardization. Still,
as mentioned above, this does not explain the different direc-
tions of regulation between the reports. In contrast to IL-18, it
was not possible to explain these different results based on a
disease progression-dependent regulation of TGF-β.
Cytokines with No or Marginal Changes in AD
Several cytokines have been intensively investigated in AD
patients without finding an induction or regulation in blood or
CSF. A good representative for this group is interleukin-2 (IL-
2), which was analyzed in three studies on CSF and seven
studies on plasma of AD patients [2, 33, 54, 67, 68, 71, 79,
89]. As all of these studies uniformly reported no changes in
CSF or plasma levels compared to controls, IL-2 is probably
not regulated in AD. Similar findings have also been docu-
mented for its receptor IL-2R and some other cytokines like
GM-CSF, IFN-γ, IL-1α, IL-1RA, and IL-3 (Supplementary
2). Still, some of these factors have barely been investigated in
the CSF of AD or MCI patients and it cannot be excluded that
changes might be visible in CSF which are undetectable in
peripheral blood.
Other Inflammation Associated Proteins
Together with cytokines, several other proteins induced by
cytokines or otherwise involved in or associated with inflam-
matory processes, like growth factors, selectins or acute phase
proteins have been investigated (Supplementary 2). The
resulting findings were often as contradictory as for cytokines,
although available data might sometimes be too scarce for
final conclusions. Two frequently analyzed examples are
alpha-1-antichymotrypsin (ACT) and brain-derived neuro-
trophic factor (BDNF):
ACT has been extensively studied in AD patients using
the methods of immunodiffusion and ELISA [30, 65, 71,
72, 87, 88, 95–100, 132–135]. Data on ACT levels in
MCI, on the other hand, are scarce. Approximately 50 %
of the articles on ACT describe modest upregulation in
AD, while the other half does not find differences in
serum or CSF. It has been stated that ACT levels might
show a weak positive correlation with disease
progression in AD, which might explain the differences
between the reports [95]. When evaluated as a biomarker,
ACT levels were insufficient to discriminate AD from
other dementias, whereas elevated levels in other diseases
lead to a high false-positive rate [132–134].
The effects reported for BDNF were mostly modest
whereas interindividual differences were high and over-
lapping between the groups [35–37, 78, 136–139]. The
largest study by O´Bryant et al. investigating nearly 100
individuals showed no differences between AD patients
and controls [140]. Therefore, smaller collectives might
provide misleading results due to the high interindividual
variances, and BDNF levels might in reality be un-
changed in AD.
Conclusions
Studies on proteins involved in immune signaling and regula-
tion often present a heterogeneous picture. Methodical vari-
ances caused by use of different ELISA kits, might be one
contributing factor to the observed discrepancies. Despite from
various diluents and detection methods, capture or detection
antibodies might recognize different antigens, resulting in the
quantification of various protein isoforms. Comparative studies
between numerous antibody-based single- and multiplex ap-
proaches for cytokine quantification and a better characteriza-
tion of the epitopes recognized by the respective antibodies
might therefore be desirable. As recently pointed out, use of
serum or plasma biobanking conditions and sample handling
may significantly affect the results of cytokine detection, which
is why improvement of standardization between research
groups should also be considered [141].
Further differences might be based on patient collective
characterization, especially in terms of disease progression, as
several studies discuss correlations of cytokine expression to
disease state [27, 29–32, 36–38, 47]. As a possible guideline
for future studies, levels of cytokines, other immune signaling
related regulators and their receptors in blood or CSF of MCI
and AD patients can be divided into five groups by involve-
ment into disease, available information and consequences for
research (Fig. 1):
The first group contains cytokines like IL-2 or IL-
1-α which are frequently and uniformly reported as
unchanged during disease progression, especially in
regard of blood levels. Of note, this does not ex-
clude any intra- and intercellular function of these
cytokines, but makes them less promising targets
for biomarker research.
The second group includes cytokines like IL-1β, IL-6,
and TNF-α which seem to increase slightly but steadily
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over the time during the course of AD, not only in the
CSF but also in blood. Members of this group often show
effects which are too small to be used as reliable bio-
markers. Aside from steady increase, there are the possi-
bilities that individuals with elevated levels of these cy-
tokines are at higher risk to develop AD or that subgroups
of AD patients display elevated levels.
The third group includes cytokines for which a
peak in mild AD or around the conversion from
MCI to AD has been documented. A longitudinal
validation of these observations seems to be a
promising target for biomarker research. Likewise,
cytokines from the second group may be success-
fully attributed to a distinct time point of disease
and thus allow for further functional insight.
The fourth group comprises the less frequently analyzed
cytokines and cytokine receptors, like CD40, which were
only investigated in a limited amount of studies and
require further validation. Studies of such cytokines, es-
pecially from CSF samples, could be a useful addition to
the large number of already existing analyses.
The last group includes cytokines like TGF-β, for which
the documented data are just too inconsistent to allow for
any interpretation. For the latter, it would helpful to
optimize the characterization of the patient collective
and to standardize the detection methods. When picking
candidates from these groups, it should be noted that pairs
of cytokines and the respective receptors or binding part-
ners (like TNF-α and TNF receptor, IL-6 and IL-6 recep-
tor or IL-18 and IL-18BP) often showed coregulation or
inverse regulation. This observation could be useful to
create ratios between cytokines and their receptors or
binding partners. Such ratios could represent more valid
and reliable biomarkers than each cytokine level alone.
Overall, there is a substantial lack of longitudinal data of
cytokine expression, which might account for much of the
contradictory results. Studies analyzing large cohorts of elder-
ly and MCI patients over several years are missing to date.
Ideally, such studies would continuously collect blood and
CSF samples according to a predefined schedule. At the same
time, clinical evaluations and cerebral imaging, along with the
detection of the classical CSF biomarkers, amyloid, tau and
phospho-tau, should be assessed and related to inflammatory
mediators. Once such studies are performed, they will provide
important information and allow for a more solid picture of the
role of cytokine expression during AD development.
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